Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo de estudio
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bioorg Med Chem ; 26(3): 566-572, 2018 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-29279243

RESUMEN

Neuropeptide Y2 receptor (Y2R) agonism is an important anorectic signal and a target of antiobesity drug discovery. Recently, we synthesized a short-length Y2R agonist, PYY-1119 (4-imidazolecarbonyl-[d-Hyp24,Iva25,Pya(4)26,Cha27,36,γMeLeu28,Lys30,Aib31]PYY(23-36), 1) as an antiobesity drug candidate. Compound 1 induced marked body weight loss in diet-induced obese (DIO) mice; however, 1 also induced severe vomiting in dogs at a lower dose than the minimum effective dose administered to DIO mice. The rapid absorption of 1 after subcutaneous administration caused the severe vomiting. Polyethylene glycol (PEG)- and alkyl-modified derivatives of 1 were synthesized to develop Y2R agonists with improved pharmacokinetic profiles, i.e., lower maximum plasma concentration (Cmax) and longer time at maximum concentration (Tmax). Compounds 5 and 10, modified with 20 kDa PEG at the N-terminus and eicosanedioic acid at the Lys30 side chain of 1, respectively, showed high Y2R binding affinity and induced significant body weight reduction upon once-daily administration to DIO mice. Compounds 5 and 10, with their relatively low Cmax and long Tmax, partially attenuated emesis in dogs compared with 1. These results indicate that optimization of pharmacokinetic properties of Y2R agonists is an effective strategy to alleviate emesis induced by Y2R agonism.


Asunto(s)
Fármacos Antiobesidad/química , Obesidad/tratamiento farmacológico , Péptido YY/química , Polietilenglicoles/química , Alquilación , Secuencia de Aminoácidos , Animales , Fármacos Antiobesidad/farmacocinética , Fármacos Antiobesidad/uso terapéutico , Perros , Eméticos/química , Eméticos/uso terapéutico , Eméticos/toxicidad , Semivida , Infusiones Subcutáneas , Ratones , Ratones Endogámicos C57BL , Ratones Obesos , Obesidad/patología , Péptido YY/farmacocinética , Péptido YY/uso terapéutico , Receptores de Neuropéptido Y/agonistas , Receptores de Neuropéptido Y/metabolismo , Vómitos/etiología
2.
Bioorg Med Chem ; 25(8): 2307-2312, 2017 04 15.
Artículo en Inglés | MEDLINE | ID: mdl-28291683

RESUMEN

Neuromedin U (NMU) is a neuropeptide known to regulate food intake and energy homeostasis that is widely distributed in the gastrointestinal tract, hypothalamus, and pituitary. A short form of NMU, porcine NMU-8 has potent agonist activity for the receptors NMUR1 and NMUR2; however, its short half-life precludes its effective use in vivo. To address this limitation, we designed and synthesized NMU-8 analogs modified by polyethylene glycol (PEG) with a molecular weight of 30kDa (PEG30k) via a variety of linkers (i.e., ω-amino- and ω-imino-carboxylic acid linker). Integrated evaluation of NMUR1 and NMUR2 binding affinities in vitro and anorectic activity in mice revealed that the introduction of a linker with a rigid ring group, e.g., 2-(piperazin-1-yl)acetic acid (PipAc), yielded a highly potent anorectic peptide, PEG30k-PipAc-NMU-8 (14), possessing improved receptor binding affinity. Subsequent optimization of the molecular weight of the PEG moiety led to the discovery of a PEG20k conjugate (15), which exhibited significant anti-obesity effect upon once-daily subcutaneous administration in diet-induced obese mice with 10% and 22% body weight loss at doses of 10 and 30nmol/kg, respectively. In addition, 15 reduced the weights of the liver and adipose tissue in a dose-dependent manner and improved the plasma biochemical parameters, e.g., insulin, glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, and total cholesterol. Thus, our results suggest that 15 (NMU-0002), which showed potent and long-lasting biological profiles in vivo, represents a candidate peptide for investigating the central and peripheral actions of NMU and its potential for clinical use.


Asunto(s)
Fármacos Antiobesidad/farmacología , Neuropéptidos/farmacología , Polietilenglicoles/química , Animales , Fármacos Antiobesidad/farmacocinética , Relación Dosis-Respuesta a Droga , Masculino , Ratones , Ratones Endogámicos C57BL , Neuropéptidos/química , Neuropéptidos/farmacocinética , Porcinos , Pérdida de Peso/efectos de los fármacos
3.
Gerodontology ; 29(2): e520-4, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21771047

RESUMEN

OBJECTIVE: The aims of this study were to examine the number of missing teeth in the people of the Edo period (or number of remaining teeth) and to contribute to the 8020 movement proposed in Japan to help people retain 20 or more of their own teeth until the age of 80. BACKGROUND: The study of dentition in ancient skeletal remains of our ancestors from multiple perspectives can yield information that can contribute to the study of physical anthropology and the leading edge of modern dental research. MATERIALS AND METHODS: The materials were 82 excavated individuals (52 males and 30 females) from 1603 to 1868 whose maxillas and mandibles were both examinable. The age and sex were estimated by anthropological methods, and the individuals were divided into five groups. The status of missing teeth was compared between groups, and a chi-square test was used to test significant differences between groups. The rates of tooth loss were examined in the maxillas and mandibles. RESULTS: In the people of the Edo period, many teeth remained in good condition until early to late middle age. There were more remaining teeth in these individuals than in modern-day individuals. However, the Edo people clearly showed increased tooth loss with age. There were no differences in tooth loss by sex. The tooth type with a high rate of tooth loss was posterior teeth, but incisor loss also occurred with ageing. Mandibular canines were most likely to be remaining. CONCLUSION: The Edo people had more remaining teeth than modern-day society. This finding was unexpected. The notion that "people of long past ages lost more teeth more quickly" does not seem to apply to people in the Edo period in Japan.


Asunto(s)
Pérdida de Diente/historia , Adulto , Factores de Edad , Femenino , Historia del Siglo XVII , Historia del Siglo XVIII , Historia del Siglo XIX , Humanos , Japón , Masculino , Persona de Mediana Edad
4.
J Med Chem ; 60(14): 6089-6097, 2017 07 27.
Artículo en Inglés | MEDLINE | ID: mdl-28657315

RESUMEN

Neuromedin U (NMU) is a neuropeptide that mediates a variety of physiological functions via its receptors, NMUR1 and NMUR2. Recently, there has been an increased focus on NMU as a promising treatment option for diabetes and obesity. A short form of NMU (NMU-8) has potent agonist activity for both receptors but is metabolically unstable. Therefore, we designed and synthesized NMU-8 analogues modified by polyethylene glycol (PEG; molecular weight, 20 kDa; PEG20k) via a linker. 3-(2-Naphthyl)alanine substitution at position 19 increased NMUR2 selectivity of NMU-8 analogues with retention of high agonist activity. Compound 37, an NMUR2-selective PEG20k analogue containing piperazin-1-ylacetyl linker, exhibited a potent body weight-lowering effect with concomitant inhibition of food intake in a dose-dependent manner (body weight loss of 12.4% at 30 nmol/kg) by once-daily repeated dosing for 2 weeks in mice with diet-induced obesity.


Asunto(s)
Fármacos Antiobesidad/síntesis química , Neuropéptidos/química , Obesidad/tratamiento farmacológico , Fragmentos de Péptidos/síntesis química , Polietilenglicoles/química , Receptores de Neurotransmisores/agonistas , Animales , Fármacos Antiobesidad/farmacocinética , Fármacos Antiobesidad/farmacología , Peso Corporal/efectos de los fármacos , Grasas de la Dieta/administración & dosificación , Masculino , Ratones Endogámicos C57BL , Naftalenos/síntesis química , Naftalenos/farmacocinética , Naftalenos/farmacología , Obesidad/fisiopatología , Fragmentos de Péptidos/farmacocinética , Fragmentos de Péptidos/farmacología , Piperazinas/síntesis química , Piperazinas/farmacocinética , Piperazinas/farmacología , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA